- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A pharmacist complained about an uninvited Meda email titled as “Patient Safety” but promoting EpiPen. PMCPA found disguised promotion and use of…
A Qutenza journal insert styled as a ‘consensus statement’ and ‘adapted from NICE’ was ruled misleading: funding/organisation by Astellas wasn’t clear upfront…
Bayer incentive scheme slides and emails pushed frequency targets (eg 50% of targets seen 3 times) without clearly stating ABPI limits. Panel…
A journalist alleged a Daily Mail Online story was covert promotion of Xolair. PMCPA assessed Novartis’ earlier press release (not the article)…
A GP complained that BuTrans ads were emailed twice to her NHS account. The Panel found evidence she had opted in via…
A GP queried whether a Cipralex promotional email sent via a third-party database was unsolicited/spam. Panel found the recipient had previously opted…
Ex-employee alleged archived investor presentations made false/imbalanced claims about Seroquel and weight gain. Panel and Appeal Board ruled no breach of Clause…
Sanofi was ruled in breach for failing to comply with an earlier PMCPA undertaking after a Lyxumia press release remained on its…
GSK voluntarily admitted a COPD NHS joint working project started and used materials before Code certification. PMCPA ruled breaches of Clauses 14.3,…
Sanofi used selective graphs from a 28‑day pharmacodynamic study to compare Lyxumia vs Victoza. The Panel said it wasn’t clear results were…
A Repatha leavepiece used a prominent ‘75% additional LDL‑C reduction vs placebo’ headline from a small study cohort. The Panel ruled the…
Pierre Fabre admitted multiple ABPI Code breaches after using and emailing uncertified cycle-meeting materials for Toviaz, including misleading comparative content and a…
Sanofi KAM business cards said “Clexane Key Account Manager” without prescribing information. Panel found the card was not promotional on the evidence…
A director of research challenged an AstraZeneca tweet claiming ~30% of women with early breast cancer develop advanced/metastatic disease. The PMCPA Panel…
A Fostair leavepiece headline (“New licence… for an extra fine day”) was ruled ambiguous, misleading and unsubstantiated (Clauses 7.2, 7.4). Separate concerns…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.